Efficacy and Safety of Nafamostat Mesylate for ECMO Anticoagulation
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to compare the efficacy and safety of nafamostat mesylate and
unfractionated heparin during ECMO anticoagulation in critically ill patients.